PURPOSE: Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and are overexpressed in Kaposi's sarcoma (KS) cells. The primary aim was to define the safety and toxicity of the MMP inhibitor COL-3 in patients with AIDS-related KS. Secondary aims were to evaluate tumor response, pharmacokinetics, and changes in blood levels of MMP-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF). PATIENTS AND METHODS: COL-3 was administered orally once daily, and doses were escalated in cohorts of three to six subjects. Patients with symptomatic visceral KS or severe tumor-associated edema were excluded. Antiretroviral therapy was permitted but not required. Study end points were grade 3 or 4 toxicity or progressive KS. Serial blood specimens were obtained for pharmacokinetics and levels of MMP-2, MMP-9, VEGF, and bFGF. RESULTS: Eighteen patients received COL-3 in dosing cohorts of 25, 50, and 70 mg/m(2)/d. Prior KS therapy was reported by 17 patients (94%). COL-3-related grade 3 or 4 adverse events were reported by six patients and included photosensitivity, rash, and headache. There was one complete response and seven partial responses, for an overall response rate of 44%, with a median response duration of 25+ weeks. The median COL-3 half-life was 39.3 hours (range, 4.1 to 251.1 hours). There was a significant difference between responders and nonresponders with respect to the change in MMP-2 serum levels from baseline to minimum value on treatment (P =.037). CONCLUSION: COL-3 administered orally once daily to patients with AIDS-related KS is reasonably well tolerated. The most common adverse event was dose-related photosensitivity. Antitumor activity was noted. Further evaluation of COL-3 for the treatment of KS is warranted.
PURPOSE: Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and are overexpressed in Kaposi's sarcoma (KS) cells. The primary aim was to define the safety and toxicity of the MMP inhibitor COL-3 in patients with AIDS-related KS. Secondary aims were to evaluate tumor response, pharmacokinetics, and changes in blood levels of MMP-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF). PATIENTS AND METHODS: COL-3 was administered orally once daily, and doses were escalated in cohorts of three to six subjects. Patients with symptomatic visceral KS or severe tumor-associated edema were excluded. Antiretroviral therapy was permitted but not required. Study end points were grade 3 or 4 toxicity or progressive KS. Serial blood specimens were obtained for pharmacokinetics and levels of MMP-2, MMP-9, VEGF, and bFGF. RESULTS: Eighteen patients received COL-3 in dosing cohorts of 25, 50, and 70 mg/m(2)/d. Prior KS therapy was reported by 17 patients (94%). COL-3-related grade 3 or 4 adverse events were reported by six patients and included photosensitivity, rash, and headache. There was one complete response and seven partial responses, for an overall response rate of 44%, with a median response duration of 25+ weeks. The median COL-3 half-life was 39.3 hours (range, 4.1 to 251.1 hours). There was a significant difference between responders and nonresponders with respect to the change in MMP-2 serum levels from baseline to minimum value on treatment (P =.037). CONCLUSION: COL-3 administered orally once daily to patients with AIDS-related KS is reasonably well tolerated. The most common adverse event was dose-related photosensitivity. Antitumor activity was noted. Further evaluation of COL-3 for the treatment of KS is warranted.
Authors: Ping Pei; Michael P Horan; Russ Hille; Craig F Hemann; Steven P Schwendeman; Susan R Mallery Journal: Free Radic Biol Med Date: 2006-07-15 Impact factor: 7.376
Authors: Mary Cianfrocca; Sandra Lee; Jamie Von Roenn; Michelle A Rudek; Bruce J Dezube; Susan E Krown; Joseph A Sparano Journal: Cancer Chemother Pharmacol Date: 2011-01-05 Impact factor: 3.333
Authors: Mina C Hosseinipour; Minhee Kang; Susan E Krown; Aggrey Bukuru; Triin Umbleja; Jeffrey N Martin; Jackson Orem; Catherine Godfrey; Brenda Hoagland; Noluthando Mwelase; Deborah Langat; Mulinda Nyirenda; John MacRae; Margaret Borok; Wadzanai Samaneka; Agnes Moses; Rosie Mngqbisa; Naftali Busakhala; Otoniel Martínez-Maza; Richard Ambinder; Dirk P Dittmer; Mostafa Nokta; Thomas B Campbell Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Thomas S Uldrick; Kathleen M Wyvill; Pallavi Kumar; Deirdre O'Mahony; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; Seth M Steinberg; Stefania Pittaluga; Vickie Marshall; Denise Whitby; Richard F Little; Robert Yarchoan Journal: J Clin Oncol Date: 2012-03-19 Impact factor: 44.544
Authors: Shreyas K Roy; Daniel Kendrick; Benjamin D Sadowitz; Louis Gatto; Kathleen Snyder; Joshua M Satalin; Lorne M Golub; Gary Nieman Journal: Pharmacol Res Date: 2011-06-21 Impact factor: 7.658